Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics Inc (NASDAQ: CYTK) is a biopharmaceutical leader pioneering muscle-targeted therapies for cardiovascular and neuromuscular diseases. This dedicated news hub provides investors and researchers with timely updates on the company's clinical developments, regulatory milestones, and strategic initiatives.
Access consolidated information on clinical trial progress, FDA communications, and research partnerships critical to understanding Cytokinetics' position in muscle biology therapeutics. Our repository ensures efficient tracking of earnings reports, intellectual property updates, and scientific advancements related to their small molecule drug candidates.
Bookmark this page for streamlined monitoring of Cytokinetics' innovations in cardiac muscle activators and neuromuscular treatments. Regular updates provide essential insights into the company's progress addressing conditions like heart failure and ALS through novel therapeutic approaches.
Cytokinetics (Nasdaq: CYTK) announced inducement equity awards dated November 15, 2025 for new hires. The company granted options to purchase 87,297 RSUs (settled in shares) to Jeffrey Hessekiel, who began employment November 14, 2025, and granted options for an aggregate of 13,175 shares plus 8,881 RSUs to three additional employees who started in October–November 2025.
RSUs vest over 3 years (40%/40%/20%). Stock options have an exercise price of $66.44 (closing price on November 14, 2025), vest over 4 years with a one-year 1/4 cliff and monthly vesting thereafter, and a 10-year term. Awards were made under the 2004 Equity Incentive Plan in accordance with Nasdaq Rule 5635(c)(4).
Cytokinetics (Nasdaq: CYTK) announced on November 17, 2025 its support for a three-year American Heart Association initiative to improve diagnosis, access, and treatment for people living with hypertrophic cardiomyopathy (HCM).
The company said it will back efforts to expand participation in a national HCM Registry powered by Get With The Guidelines®, broaden certification for referring centers, introduce patient support services at key HCM centers, and pilot the Association’s HCM detection algorithm to reduce underdiagnosis.
The initiative targets systemic barriers to more consistent, equitable care for the estimated one in 500 U.S. people living with HCM.
Cytokinetics (Nasdaq: CYTK) announced additional MAPLE-HCM data presented Nov 10, 2025 showing aficamten was superior to metoprolol on multiple clinical measures after 24 weeks.
Key findings: a pre-specified responder analysis found 78% of aficamten patients had a positive/complete response vs 3% with metoprolol (p<0.001). Patient-reported outcomes improved more with aficamten (KCCQ-OSS 16.6 vs 8.9; between-group difference = 7.8 points, p=0.001). NT-proBNP fell 73% on aficamten vs rose 42% on metoprolol (treatment effect -81%, p<0.001); hs-cTnI fell 43% vs 17% (treatment effect -28%, p=0.001).
Overall AE rates were similar (73.9% aficamten vs 75.9% metoprolol); hypertension was more frequent with aficamten (10.2% vs 2.3%) and dizziness more frequent with metoprolol (17.2% vs 5.7%).
Cytokinetics (NASDAQ: CYTK) reported Q3 2025 results and a business update ahead of a PDUFA action date of December 26, 2025 for aficamten for obstructive HCM. The company reported approximately $1.25 billion in cash, cash equivalents and investments as of September 30, 2025, and completed a $750.0 million convertible notes offering in September 2025.
Clinical highlights include MAPLE-HCM superiority on pVO2 (+2.3 mL/kg/min, p<0.001) versus metoprolol and ongoing global regulatory reviews with an EMA decision possible in 1H 2026. Financials: Q3 revenue $1.9M, R&D expense $99.2M, G&A expense $69.5M, and net loss $306.2M (includes $121.2M debt conversion expense). 2025 GAAP operating expense guidance updated to $680M–$700M.
Cytokinetics (Nasdaq: CYTK) said members of its management team will participate in two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on Tuesday, November 11, 2025 at 11:20 AM ET in New York, and a Jefferies Global Healthcare Conference fireside chat on Monday, November 17, 2025 at 2:30 PM GMT in London.
Interested parties can access live webcasts via the Investors & Media section of the Cytokinetics website. Webcast replays will be archived on the site for 90 days after each event.
Cytokinetics (Nasdaq: CYTK) announced multiple presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on November 7, 2025 and the American Heart Association Scientific Sessions November 7–10, 2025 in New Orleans.
Highlights include three Late Breaking Science presentations and multiple oral, poster and moderated poster sessions covering MAPLE-HCM (aficamten vs metoprolol), FOREST-HCM, SEQUOIA-HCM and other HCM and heart-failure trial insights.
Cytokinetics (Nasdaq: CYTK) will report third quarter 2025 results on November 5, 2025 at 4:00 PM Eastern Time. Senior management will host a conference call at 4:30 PM ET to discuss financial results and business updates. The call will be webcast live and accessible from the Investors & Media section of Cytokinetics' website or via the provided Cytokinetics Q3 2025 Earnings Conference Call link.
An archived replay of the webcast will be available on the company's website for six months.
Cytokinetics (Nasdaq: CYTK) announced on October 17, 2025 that on October 15, 2025 it granted inducement equity awards to 83 new employees who began in September and October 2025.
The grants consist of 109,120 stock options and 73,535 RSUs. Options carry a $62.80 exercise price (the October 15, 2025 closing price) and a 10‑year term. RSUs vest over 3 years (40%/40%/20% on years 1/2/3). Options vest over 4 years (25% at year 1, then monthly over 36 months), all subject to continued service and the company's equity plan. Awards were granted as material inducements under Nasdaq Listing Rule 5635(c)(4).
Cytokinetics (NASDAQ:CYTK) presented new data for aficamten at the HFSA Annual Scientific Meeting 2025, showcasing positive results from two studies. The MAPLE-HCM study demonstrated aficamten's superiority over metoprolol in improving exercise capacity, with significant enhancements in both maximal and submaximal exercise performance.
The FOREST-HCM 96-week analysis in non-obstructive HCM patients showed promising long-term efficacy and tolerability. Key findings include 79% of patients improving by at least one NYHA Functional Class, with 74% becoming asymptomatic. The study reported sustained reductions in symptom burden and improvements in cardiac biomarkers, with 82.4% of patients achieving the highest available doses of 15-20 mg.
Cytokinetics (Nasdaq: CYTK) has announced its eighth annual Communications Grant Program, which will award five grants to patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure communities. The program aims to support communications, awareness building, and community engagement initiatives.
Applications for the 2025 grants are open until November 3rd, 2025, with winners to be announced in January 2026. Eligible organizations must be nonprofits or registered charities in the US, Canada, Europe, or UK. Previous recipients include the AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, HCMA, and Stichting Cardiomyopathie Onderzoek Nederland.
FAQ
What is the current stock price of Cytokinetics (CYTK)?
What is the market cap of Cytokinetics (CYTK)?
